406 related articles for article (PubMed ID: 24507812)
1. Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.
Itzykson R; Kosmider O; Fenaux P
Best Pract Res Clin Haematol; 2013 Dec; 26(4):355-64. PubMed ID: 24507812
[TBL] [Abstract][Full Text] [Related]
2. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
3. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
4. The molecular pathogenesis of the myelodysplastic syndromes.
Pellagatti A; Boultwood J
Eur J Haematol; 2015 Jul; 95(1):3-15. PubMed ID: 25645650
[TBL] [Abstract][Full Text] [Related]
5. Genetics factors associated with myelodysplastic syndromes.
Macedo LC; Silvestre AP; Rodrigues C; de Alencar JB; Zacarias JM; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2015 Jun; 55(1):76-81. PubMed ID: 25976472
[TBL] [Abstract][Full Text] [Related]
6. Genetic abnormalities and pathophysiology of MDS.
Hosono N
Int J Clin Oncol; 2019 Aug; 24(8):885-892. PubMed ID: 31093808
[TBL] [Abstract][Full Text] [Related]
7. Concurrent mutations in other epigenetic modulators portend better prognosis in BCOR-mutated myelodysplastic syndrome.
Badaat I; Mirza S; Padron E; Sallman D; Komrokji R; Song J; Hussaini MO
J Clin Pathol; 2020 Apr; 73(4):209-212. PubMed ID: 31771970
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
9. The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.
Larsson CA; Cote G; Quintás-Cardama A
Mol Cancer Res; 2013 Aug; 11(8):815-27. PubMed ID: 23645565
[TBL] [Abstract][Full Text] [Related]
10. Genetics of myelodysplastic syndromes: new insights.
Graubert T; Walter MJ
Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
[TBL] [Abstract][Full Text] [Related]
11. Integrating genetics and epigenetics in myelodysplastic syndromes: advances in pathogenesis and disease evolution.
Bravo GM; Lee E; Merchan B; Kantarjian HM; García-Manero G
Br J Haematol; 2014 Sep; 166(5):646-59. PubMed ID: 24903747
[TBL] [Abstract][Full Text] [Related]
12. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
13. Mutations in epigenetic regulators in myelodysplastic syndromes.
Nikoloski G; van der Reijden BA; Jansen JH
Int J Hematol; 2012 Jan; 95(1):8-16. PubMed ID: 22234528
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
15. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
Zhang L; Padron E; Lancet J
Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
[TBL] [Abstract][Full Text] [Related]
16. [A novel prognostic model incorporating genetic profiling for myelodysplastic syndromes].
Nagata Y; Ogawa S
Rinsho Ketsueki; 2017; 58(7):776-786. PubMed ID: 28781274
[TBL] [Abstract][Full Text] [Related]
17. Life after hypomethylating agents in myelodysplastic syndrome: new strategies.
Santini V
Curr Opin Hematol; 2015 Mar; 22(2):155-62. PubMed ID: 25603477
[TBL] [Abstract][Full Text] [Related]
18. Epigenetics in myelodysplastic syndromes.
Heuser M; Yun H; Thol F
Semin Cancer Biol; 2018 Aug; 51():170-179. PubMed ID: 28778402
[TBL] [Abstract][Full Text] [Related]
19. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
20. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.
Cedena MT; Rapado I; Santos-Lozano A; Ayala R; Onecha E; Abaigar M; Such E; Ramos F; Cervera J; Díez-Campelo M; Sanz G; Rivas JH; Lucía A; Martínez-López J
Oncotarget; 2017 Dec; 8(63):106948-106961. PubMed ID: 29291002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]